Cyfuse Biomedical KK (TSE:4892) Debt-to-Equity : 0.27 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Debt-to-Equity?

Cyfuse Biomedical KK's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円468.00 Mil. Cyfuse Biomedical KK's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円336.00 Mil. Cyfuse Biomedical KK's Total Stockholders Equity for the quarter that ended in Jun. 2024 was 円2,931.03 Mil. Cyfuse Biomedical KK's debt to equity for the quarter that ended in Jun. 2024 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cyfuse Biomedical KK's Debt-to-Equity or its related term are showing as below:

TSE:4892' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.27 Max: 0.41
Current: 0.27

During the past 4 years, the highest Debt-to-Equity Ratio of Cyfuse Biomedical KK was 0.41. The lowest was 0.24. And the median was 0.27.

TSE:4892's Debt-to-Equity is ranked better than
51.15% of 829 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs TSE:4892: 0.27

Cyfuse Biomedical KK Debt-to-Equity Historical Data

The historical data trend for Cyfuse Biomedical KK's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Debt-to-Equity Chart

Cyfuse Biomedical KK Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.34

0.30

0.24

0.29

Cyfuse Biomedical KK Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial						0.25	0.25	0.29	0.27	0.27

Competitive Comparison of Cyfuse Biomedical KK's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyfuse Biomedical KK's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Debt-to-Equity falls into.

Cyfuse Biomedical KK Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cyfuse Biomedical KK's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(568	+	345)	/	3203.469
	=	0.29

Cyfuse Biomedical KK's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(468	+	336)	/	2931.032
	=	0.27

Cyfuse Biomedical KK (TSE:4892) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cyfuse Biomedical KK Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyfuse Biomedical KK Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN

Website

https://www.cyfusebio.com

Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK Headlines

No Headlines